Melanoma Clinical Trials in San Francisco

Showing 121-140 of 151 trials

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

NCT02413827

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab, CDX-1401 and poly-ICLC. The study will enroll patients with unresectable Stage III or Stage IV melanoma.

Unresectable Stage III or Stage IV Melanoma

Celldex Therapeutics9 participantsStarted Apr 2015

San Francisco, California, United States • Santa Rosa, California, United States • Aurora, Colorado, United States +5 more locations

WITHDRAWNPhase 2< 1 mile

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

NCT02400385

This will be a phase II trial of the combination of sunitinib and nivolumab in patients with advanced, measurable, metastatic melanoma who harbor mutations in the KIT gene in their tumors. It is a multi-center trial using the FDA-approved doses of both sunitinib and nivolumab. Sunitinib will be provided by Pfizer. Endpoint is RECIST response rate and PFS.

Melanoma

California Pacific Medical Center Research InstituteStarted Oct 2014

San Francisco, California, United States

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Melanoma Trials in Other Cities

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Clinical Trial of Sutent to Treat Metastatic Melanoma

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

B-Receptor Signaling in Cardiomyopathy

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

A Study of Vemurafenib in Participants With Metastatic Melanoma

Other Conditions in San Francisco